On Monday, BofA Securities adjusted its price target for Bruker (NASDAQ:BRKR) Corporation (NASDAQ:BRKR), a scientific instruments manufacturer, to $90 from the previous $95, while maintaining a Buy rating on the stock. The adjustment follows Bruker's recent modeling update call and a series of mergers and acquisitions, most notably the acquisition of Nanostring.
Bruker provided an updated mid-term outlook, now projecting fiscal year 2027 revenues to be between $4.2 billion and $4.4 billion, with adjusted operating margins (Adj OpM) of 19%-20%, and adjusted earnings per share (Adj EPS) ranging from $4.00 to $4.30.
This forecast is an increase from the original fiscal year 2026 targets, which had been advanced to fiscal year 2025 during the fourth quarter of 2023, with revenue goals of $3.4 billion to $3.6 billion and an Adj EPS of $3.40 to $3.70.
Management did not provide explicit guidance for fiscal years 2025 or 2026, but sales and adjusted earnings per share for these periods are expected to exceed $3.7 billion and approximately $3.10, and be around $4.0 billion and approximately $3.65, respectively.
For the more immediate term, Bruker refrained from offering specific guidance on the results from Nanostring Technologies for fiscal years 2024 and 2025 due to uncertainties stemming from the company's Chapter 11 bankruptcy and ongoing litigation.
However, Bruker anticipates more than $80 million from around seven months of inorganic revenue contribution and still expects a dilution of 15 to 20 cents, leading to a revised fiscal year 2024 implied earnings per share of $2.59 to $2.69.
Additionally, Bruker indicated that their second quarter of 2024 is tracking slightly ahead of expectations, with the company now forecasting high single-digit organic growth compared to the previous guidance of mid-single-digit-plus growth. This update provides investors with a glimpse into the company's performance and expectations in the near term.
InvestingPro Insights
As investors digest the recent updates from Bruker Corporation, including the revised mid-term outlook and the performance expectations for the second quarter of 2024, it's worth considering additional insights from InvestingPro. Bruker is currently trading at a P/E ratio of 27.28, which is considered low relative to its near-term earnings growth. This suggests that the stock may be undervalued, offering an attractive entry point for investors who are bullish on the company's prospects. Additionally, Bruker's cash flows have been robust enough to cover interest payments, reflecting financial stability and a manageable debt level.
InvestingPro data shows a strong revenue growth of 14.49% over the last twelve months as of Q1 2024, with a gross profit margin of 50.61%, indicating efficient operations and profitability. While the company is trading at a high Price/Book multiple of 7.71, it is important to note that analysts predict Bruker will be profitable this year, having been profitable over the last twelve months, and has shown a high return over the last decade.
For investors seeking more comprehensive analysis, there are additional InvestingPro Tips available, including insights on the company's EBITDA valuation multiple and analyst revisions on earnings. Discover more tips and enhance your investment strategy with an exclusive offer: use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription at InvestingPro. There are currently 8 more tips listed in InvestingPro that could further inform your investment decisions regarding Bruker Corporation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.